SCHEMBL764133

SCHEMBL764133

CCNc1ncc(C)c(Nc2cccc3ccccc23)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 1/20 0.51
SYK P43405 3/20 0.47
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
BLM P54132 1/20 0.43
KMT2A Q03164 1/20 0.43
AURKA O14965 1/20 0.42
EPHX2 P34913 1/20 0.42
EGFR P00533 2/20 0.41
KDR P35968 1/20 0.41
JAK3 P52333 1/20 0.41
CCR4 P51679 2/20 0.41
SLC2A1 P11166 1/20 0.41
CDC25A P30304 1/20 0.40
CDC25B P30305 1/20 0.40
CDC25C P30307 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19654290 0.88 ULK1 (0.64) ULK1SYKALDH1A1MAPTSMN1; SMN2
SCHEMBL17916066 0.85 ULK1 (0.54) ULK1SYKALDH1A1MAPTSMN1; SMN2
SCHEMBL301971 0.84 TP53 (0.43) SYKMAPTSMN1; SMN2TP53AURKA
SCHEMBL306611 0.83 EGFR (0.42) SYKAURKAEGFRJAK3SLC2A1
SCHEMBL13494299 0.82 SYK (0.52) SYKEGFRKDRJAK3CCR4
SCHEMBL302254 0.82 SYK (0.52) SYK
SCHEMBL270620 0.82 ULK1 (0.54) ULK1SYKALDH1A1MAPTSMN1; SMN2
SCHEMBL12279154 0.80 EGFR (0.53) ULK1ALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL301101 0.80 PKM (0.37) SYKAURKAEGFRJAK3SLC2A1
SCHEMBL301484 0.79 EGFR (0.57) SYKAURKAEGFRKDRJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951684-B1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN INC (US) 2016-07-13 EP disclosed
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 US disclosed
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-09-01 US disclosed
US-7825246-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2010-11-02 US disclosed
WO-2010017122-A2 METHODS OF TREATING THALASSEMIA TARGEGEN INC. (US) 2010-02-11 WO disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 ULK1 514/4885SYK 281/4885ALDH1A1 3235/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 ULK1 514/4885SYK 281/4885ALDH1A1 3235/4885
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES JAK2, TYK2, JAK3 ULK1 514/4885SYK 281/4885ALDH1A1 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.